Clinical News

Buckley, Peter F.
April 2013
Clinical Schizophrenia & Related Psychoses;Apr2013, Vol. 7 Issue 1, p13
Academic Journal
The article offers world news briefs related to psychiatry. Dr. Robert Buchanan, professor of psychiatry at the University of Maryland School of Medicine, has received the 2012 Stanley Dean Award for Research in Schizophrenia. The U.S. Food and Drug Administration (FDA) has approved Staccato laxapine for the treatment of agitation associated with either schizophrenia or bipolar disorder. Alkermes PLC has advanced to Phase 2 clinical trial for a novel antipsychotic.


Related Articles

  • Pipeline preview.  // Formulary;Feb2009, Vol. 44 Issue 2, p32 

    A list of drugs at various stages in the U.S. Food and Drug Administration (FDA) approval pipeline is presented, including Asenapine (Saphris), Certolizumab pegol (Cimzia), and Olanzapine.

  • Week in Washington.  // BioWorld Insight;7/16/2012, Vol. 20 Issue 29, p6 

    The article offers the U.S. Food and Drug Administration news brief as of July 2012 on the topics including approval of the Food and Drug Administration (FDA) to risk evaluation of opioid drugs, signing of FDA Safety and Innovation Act and suing of FDA by K-V Pharmaceuticals Inc.

  • FDA's Consideration of Evidence from Certain Clinical Trials. Crosse, Marcia // GAO Reports;8/30/2010, preceding p1 

    The article discusses a study conducted by the U.S. Government Accountability Office (GAO) on the Food and Drug Administration's (FDA's) decision for drug approval. The GAO examined the FDA's use of non-inferiority trial evidence to assess drug effectiveness by looking at new drug applications...

  • Pipeline preview.  // Formulary;Feb2010, Vol. 45 Issue 2, p41 

    The article discusses the status of various drugs in the U.S. Food and Drug Administration (FDA) approval process. The drugs recommended for approval include Carglumic acid for the treatment of patients with N acetyle glutamate sythetase (NAGS) deficiency and Miglustat for the treatment of...

  • A New Drug for an Old Nemesis. Kabat, Alan G.; Sowka, Joseph W. // Review of Optometry;Dec2009, Vol. 146 Issue 12, p69 

    The article focuses on the approval of Zirgan, a formulation of ganciclovir in a topical gel form, by the U.S. Food and Drug Administration (FDA). It notes that this FDA approved drug is for treating herpetic keratitis. Furthermore, the drug's approval is based on results of Virgan clinical...

  • Vectical Ointment.  // Formulary;Mar2009, Vol. 44 Issue 3, p71 

    The article reports on the approval by the U.S. Food and Drug Administration (FDA) on calcitriol, a vitamin D analogue for topical treatment of mild-to-moderate plaque psoriasis in adults, on January 23, 2009. The efficacy of the agent was assessed in two multicenter and observed that...

  • Review and Approval of Oncology and Hematology Drugs at FDA from 2005 to 2007.  // JNCI: Journal of the National Cancer Institute;2/24/2010, Vol. 102 Issue 4, pNP 

    The article focuses on a report in the January 29, 2010 issue of the "Journal of the National Cancer Institute," which indicated that of the 60 new oncology and hematology drugs reviewed by the U.S. Food and Drug Administration's oncology drug product's office since 2005, 53 received approval....

  • Review of Oncology and Hematology Drug Product Approvals at the US Food and Drug Administration Between July 2005 and December 2007. Sridhara, Rajeshwari; Johnson, John R.; Justice, Robert; Keegan, Patricia; Chakravarty, Aloka; Pazdur, Richard // JNCI: Journal of the National Cancer Institute;2/24/2010, Vol. 102 Issue 4, p230 

    Background: The Office of Oncology Drug Products (OODP) in the Center for Drug Evaluation and Research at the US Food and Drug Administration began reviewing marketing applications for oncological and hematologic indications in July 2005. We conducted an overview of products that were reviewed...

  • FDA Speeds More Breakthrough Drugs to Market. Wechsler, Jill // Applied Clinical Trials;Feb2013, Vol. 22 Issue 2, p10 

    The article discusses the U.S. Food and Drug Administration (FDA) Safety & Innovation Act (FDASIA) for improving innovation in drugs of critical therapies. According to John Jenkins, director of the Office of New Drugsin the Center for Drug Evaluation and Research (CDER), FDA approved clinical...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics